Outcomes |
Primary study outcome
Interleukins
Ferritin
Dimder‐D
Review outcomes
All‐cause mortality at day 28, day 60, time‐to‐event, and at hospital discharge ‐ NP
-
Clinical status, assessed by need for respiratory support with standardised scales (e.g. WHO Clinical Progression Scale (WHO 2020e), WHO Ordinal Scale for Clinical Improvement (WHO 2020f)) at day 28, day 60, and up to longest follow‐up); including:
Need for dialysis (at up to 28 days) ‐ NP
Quality of life, including fatigue and neurological status, assessed with standardised scales (e.g. WHOQOL‐100) at up to seven days; up to 30 days, and longest follow‐up available ‐ NP
Admission to ICU ‐ NP
Duration of hospitalisation ‐ NP
Time to discharge from hospital ‐ NP
Viral clearance, assessed with reverse transcription polymerase chain reaction (RT‐PCR) test for SARS‐CoV‐2 at baseline, up to 3, 7, and 15 days ‐ NP
Vitamin D serum levels ‐ reported
Serious adverse events, defined as number of participants with event ‐ NP
Adverse events (any grade, grade 1‐2, grade 3‐4), defined as number of participants with event ‐ NP
Additional study outcomes:
|